DEXINEURO® Tab on Blood Glucose Reduction in Patients With Type 2 Diabetes Accompanied by Diabetic Peripheral Neuropathy

Inclusion Criteria: 1. Adults aged 19 years and older of both genders. 2. Type 2 diabetes patients with HbA1c ≤ 10% at screening. 3. Patients diagnosed with diabetic peripheral neuropathy who are scheduled to receive DEXINEURO® tab. 4. Individuals who have voluntarily provided written consent to participate in this study. Exclusion Criteria: 1. Individuals who have taken or are currently taking alpha-lipoic acid (thioctic acid) within 1 month before screening. 2. Individuals contraindicated according to the approval conditions of DEXINEURO® tab. 3. Pregnant or breastfeeding women. 4. Individuals participating in other clinical trials (except for non-interventional observational studies, if they have not received investigational drugs, or are participating in other non-interventional observational studies). 5. Individuals whom the principal investigator deems inappropriate for participation in this study for reasons other than those mentioned above.